Group 1 - Haichuang Pharmaceutical increased by over 10% [1] - Frontier Biotech rose by over 8% [1] - Yuekang Pharmaceutical, Rejing Biotech, Huisheng Biotech, and Zhongsheng Pharmaceutical also experienced gains [1]

每经AI快讯，有投资者在投资者互动平台提问：上市半年了，医疗工作者有实际使用吗？众生也没有 回应医院使用情况。 众生药业（002317.SZ）12月10日在投资者互动平台表示，公司正在稳步推进昂拉地韦片的商业化工 作。昂地拉韦片目前可在全国多个省份的公立医疗机构，主流连锁药店，或京东、天猫、美团等互联网 平台上问诊并购买。 （文章来源：每日经济新闻） ...

每经AI快讯，有投资者在投资者互动平台提问：昂拉地韦青少年三期临床和颗粒的三期临床，设计试 验周期是多长时间？ （记者 胡玲） 众生药业（002317.SZ）12月10日在投资者互动平台表示，公司组织昂拉地韦片治疗12~17岁青少年单纯 性甲型流感患者和昂拉地韦颗粒治疗2~11岁儿童单纯性甲型流感患者的两项III期临床试验，两项III期 临床研究设计为每日用药1次，共服药5天，目前均已完成所有参与者入组。公司将有序推进项目开发工 作。 ...

Group 1 - On December 8, a total of 12 companies were investigated by institutions, with 10 of them being surveyed by funds, highlighting a significant interest in Hengtong Optic-Electric, which attracted 12 fund participants [1] - The surveyed companies included 2 from the main board of the Shenzhen Stock Exchange, 6 from the ChiNext board, and 2 from the main board of the Shanghai Stock Exchange, indicating a diverse representation across different market segments [1] - The companies under investigation spanned 7 industries, with the electronics, machinery equipment, and pharmaceutical sectors having the highest representation, each featuring 2 stocks [1] Group 2 - Among the surveyed companies, 2 had a total market capitalization exceeding 50 billion yuan, while 7 had a market capitalization below 10 billion yuan, including companies like Yingli Co., Ltd., Yalian Machinery, and Taili Technology [1] - In terms of market performance, 4 out of the surveyed stocks increased in value over the past 5 days, with the highest gains seen in Boin Special Welding (26.53%), Chaojie Co., Ltd. (17.69%), and Taili Technology (1.68%); conversely, 6 stocks experienced declines, with the largest drops in China Merchants Energy (-13.66%), Zhongsheng Pharmaceutical (-9.67%), and Yingli Co., Ltd. (-2.72%) [1]

Group 1: Investor Relations Activity - The investor relations activity involved a meeting with analysts from Morgan Fund Management, Guolian Minsheng Securities, and Shenzhen Yide Global Fund Management on December 8, 2025 [1] - The meeting was held in the company conference room and included discussions on the company's new drug inclusion in the national medical insurance directory [1] Group 2: New Drug Inclusion - The innovative drug, Olanavir Tablets (brand name: Anruiwei®), was included in the National Medical Insurance Directory on December 7, 2025, following negotiations with the National Healthcare Security Administration [1][3] - Other core products such as Liraglutide Tablets and various capsules were also included in this directory, enhancing their market accessibility [1] Group 3: Drug Characteristics - Olanavir Tablets are the world's first oral drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, approved for adult patients with uncomplicated influenza [3][4] - The drug demonstrates rapid symptom relief, strong antiviral effects, and low resistance rates, with positive results from clinical trials [4][5] Group 4: Sales and Marketing Strategy - The company plans to enhance marketing through three dimensions: building an academic ecosystem, upgrading data services, and implementing key project practices [8] - The inclusion of Olanavir Tablets in the National Medical Insurance Directory is expected to positively impact market promotion and long-term business development [8] Group 5: Pediatric Development Plans - The company is developing Olanavir Granules for children and adolescents, with ongoing Phase III clinical trials for both adolescents (ages 12-17) and children (ages 2-11) [9][11] - The trials aim to establish a comprehensive treatment matrix for influenza across all age groups [11] Group 6: Other Drug Developments - RAY1225 injection, an innovative dual-agonist drug for type 2 diabetes and obesity, has shown positive results in Phase II clinical trials and is progressing to Phase III trials [12][13] - ZSP1601 tablets, targeting metabolic dysfunction-related fatty liver disease, have completed early clinical trials with promising results and are moving into Phase IIb trials [15][16] Group 7: Research and Development Pipeline - The company is focusing on innovative drug development in respiratory and metabolic diseases, with projects targeting unmet clinical needs [16][18] - Ongoing research includes a new drug for respiratory syncytial virus (RSV) and various GLP-1 receptor agonists, with clinical candidates identified and preclinical studies underway [16][18]

（记者 胡玲） 众生药业（002317.SZ）12月8日在投资者互动平台表示，公司正在稳步推进昂拉地韦片的商业化工作。 昂地拉韦片目前可在全国多个省份的公立医疗机构，主流连锁药店，或京东、天猫、美团等互联网平台 上问诊并购买。 每经AI快讯，有投资者在投资者互动平台提问：贵公司昂拉地韦怎么在医院没有实际应用？没有医疗 工作者实际验证，只有网购平台有售卖，有啥深层次原因吗？ ...

Core Viewpoint - The company Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced that its innovative drug, Angladiwei Tablets (brand name: Anruiwei), has been included in the National Medical Insurance Directory for 2025, which is expected to enhance market promotion and sales potential for the product [1][2]. Group 1: Product Information - Angladiwei Tablets are the world's first targeted drug for the PB2 subunit of the influenza A virus RNA polymerase, approved for treating adult patients with uncomplicated influenza [2]. - The drug is characterized by rapid action, strong efficacy, and low resistance, providing a cost-effective and accessible treatment option for patients [2]. Group 2: Market Impact - The inclusion of Angladiwei Tablets in the National Medical Insurance Directory is anticipated to positively impact the company's long-term operational development and market presence [2]. - Other core products of the company, including Lai Ru Te Wei Tablets and various other formulations, continue to be listed in the National Medical Insurance Directory, supporting the company's overall product portfolio [1].

Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has successfully included its innovative drug, Anladiwei Tablets (brand name: Anruiwei), in the National Medical Insurance Directory for 2025, which is expected to enhance patient access to effective treatment for influenza [1] Group 1: Product Inclusion - Anladiwei Tablets is the first global drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, approved for the treatment of uncomplicated influenza in adults [1] - The drug is characterized by rapid action, strong efficacy, and low resistance, providing a significant option for patients suffering from influenza [1] - Other core products of the company, including Lai Ru Te Wei Tablets and various formulations, continue to be included in the National Medical Insurance Directory [1] Group 2: Market Impact - The inclusion of Anladiwei Tablets in the Class B category of the National Medical Insurance Directory is expected to benefit a larger patient population, offering economical, safe, and accessible medication options [1] - The drug was approved by the National Medical Products Administration in May 2025, marking a significant milestone for the company's respiratory pipeline [1]

众生药业公告称，2025年12月7日消息，公司一类创新药物昂拉地韦片通过国家医保谈判，首次被纳入 《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》。该药品于2025年5月获批上市，适 用于成人单纯性甲型流感患者治疗。其入选有望惠及更多患者，利于产品推广销售，对公司长期经营有 积极影响，但受行业政策和市场环境影响，药品销售有不确定性，短期不会对业绩产生重大影响。 ...

Core Viewpoint - Zhongsheng Pharmaceutical's innovative drug, Angladiwei Tablets (brand name: Anruiwei), has been included in the National Medical Insurance Directory for the first time through national medical insurance negotiations [1] Group 1: Company Developments - The company announced that its core product, Lai Ru Te Wei Tablets, along with several other products, continues to be included in the National Medical Insurance Directory [1]